Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5-iodo-4-hydroxy-3-nitrophenylacetyl (NIP) is a synthetic hapten widely utilized in immunological research as a model antigen (PubChem CID: 12313450). As a hapten, it is a small molecule that is not immunogenic by itself but can elicit a robust immune response when conjugated to a larger carrier protein like bovine serum albumin (BSA) or chicken gamma globulin (CGG) (PubMed: 701734). It is frequently employed in studies of B-cell activation, antibody affinity maturation, and the structural basis of antigen-antibody interactions (PubMed: 6159784). Researchers often use NIP alongside its analog, 4-hydroxy-3-nitrophenylacetyl (NP), to measure changes in antibody affinity, as specific mutations in immunoglobulin genes can shift preference between these two related structures (PubMed: 3917421). While it is a critical tool for understanding the immune system, it is not a therapeutic target or a biological receptor found naturally in the human body.
Not applicable; NIP is a synthetic hapten used in research to study antibody production and affinity maturation rather than a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-iodo-4-hydroxy-3-nitrophenylacetyl (NIP).